TGF␤ superfamily ligands, receptors, and second messengers, including activins A and B, have been identified in pancreatic islets and proposed to have important roles regulating development, proliferation, and function. We previously demonstrated that Fstl3 (an antagonist of activin activity) null mice have larger islets with ␤-cell hyperplasia and improved glucose tolerance and insulin sensitivity in the absence of altered ␤-cell proliferation. This suggested the hypothesis that increased activin signaling influences ␤-cell expansion by destabilizing the ␣-cell phenotype and promoting transdifferentiation to ␤-cells. We tested the first part of this hypothesis by treating ␣-and ␤-cell lines and sorted mouse islet cells with activin and related ligands. Treatment of the ␣TC1-6 ␣ cell line with activins A or B suppressed critical ␣-cell gene expression, including Arx, glucagon, and MafB while also enhancing ␤-cell gene expression. In INS-1E ␤-cells, activin A treatment induced a significant increase in Pax4 (a fate determining ␤-cell gene) and insulin expression. In sorted primary islet cells, ␣-cell gene expression was again suppressed by activin treatment in ␣-cells, whereas Pax4 was enhanced in ␤-cells. Activin treatment in both cell lines and primary cells resulted in phosphorylated mothers against decapentaplegic-2 phosphorylation. Finally, treatment of ␣TC1-6 cells with activins A or B significantly inhibited proliferation. These results support the hypothesis that activin signaling destabilized the ␣-cell phenotype while promoting a ␤-cell fate. Moreover, these results support a model in which the ␤-cell expansion observed in Fstl3 null mice may be due, at least in part, to enhanced ␣-to ␤-cell transdifferentiation. (Endocrinology 156:  2440 -2450, 2015) D iabetes, a disease affecting nearly 10% of Americans, results from loss of functional insulin-producing ␤-cells, a condition that results in elevated serum glucose and eventually life-threatening morbidities. Increased functional ␤-cell mass usually compensates for enhanced insulin demand, suggesting that local and/or systemic factors can influence ␤-cell survival, proliferation, neogenesis, and/or insulin secretion (1). Identification and functional characterization of these factors may lead to targets for developing novel diabetes therapies.
D
iabetes, a disease affecting nearly 10% of Americans, results from loss of functional insulin-producing ␤-cells, a condition that results in elevated serum glucose and eventually life-threatening morbidities. Increased functional ␤-cell mass usually compensates for enhanced insulin demand, suggesting that local and/or systemic factors can influence ␤-cell survival, proliferation, neogenesis, and/or insulin secretion (1) . Identification and functional characterization of these factors may lead to targets for developing novel diabetes therapies.
The list of candidate regulatory factors includes hormones such as insulin, IGF-1, glucagon-like peptide 1, and estrogen as well as nutrients and metabolic factors such as glucose and cAMP (2, 3) . In addition, numerous members of the TGF␤ superfamily of growth factors have been attributed a variety of roles in islet biology including development of the pancreas and islets (4), regulation of ␤-cell function including insulin production and secretion (5, 6) , and modulating ␤-cell proliferation (7) . TGF␤ superfamily ligands typically bind specific type II receptors, which complex with and activate specific type 1 receptors. Activated type 1 receptors then phosphorylate subsets of mothers against decapentaplegic (Smad) second messen-gers, including Smad2 and Smad3 for activins, TGF␤, myostatin (MSTN), and growth and differentiation factor 11 and Smad1, Smad5, and Smad8/9 for bone morphogenetic proteins (BMPs) and related ligands (8 -10) , although exceptions to this canonical signaling pathway have been described. Inhibition of activin/TGF␤ signaling using dominant-negative activin type II receptors resulted in ␤-cell hypoplasia and hyperglycemia, suggesting that this pathway may regulate ␤-cell proliferation or survival (11) . Inhibition of this pathway in adult islets by inducible overexpression of the Smad2/3 antagonist Smad7 also resulted in ␤-cell hypoplasia and diabetes, which was reversed by the removal of the Smad7 inducer (12) .
On the other hand, it was recently demonstrated that increased Smad7 expression reduced Smad2/3 signaling but enhanced ␤-cell proliferation (7) , suggesting that activin and TGF␤ inhibit ␤-cell proliferation in some circumstances. Activin was also found to regulate ␤-cell maturity through the decreased expression of insulin, MafA, and Glut2 (also called Slc2a2) mRNA (6) . In addition, activins A and B were recently suggested to have opposing effects in insulin secretion by selectively using Smad2 (activin A) or Smad3 (activin B) second messengers, whereas inactivation of Inhbb (activin B subunit) enhanced insulin release (13) , although this finding has not been universally observed (14) . TGF␤, acting through Smad3, inhibited insulin biosynthesis and glucose-stimulated insulin secretion in rat islets, whereas the suppression of Smad3 expression increased ␤-cell function in mice (15) . Loss of BMP4 signaling suppressed ␤-cell function in mice, whereas the injection of BMP4 enhanced insulin secretion (16) . Taken together, these studies demonstrate important intraislet communication roles for numerous TGF␤ superfamily ligands that are important for maintaining glucose homeostasis in adults.
Activin bioactivity is antagonized by follistatin and follistatin like-3 (FSTL3) (17, 18) . We previously demonstrated that Fstl3-null mice have 2-fold larger islets with ␤-cell hyperplasia in the context of improved glucose tolerance and insulin sensitivity (19) . Importantly, ␤-cell proliferation was not different between WT and Fstl3 knockout littermates (20) , suggesting that the additional ␤-cells in Fstl3-null mice might be derived from alternative processes. The transcription factors Arx and Pax4 are required to specify fates for ␣-and ␤-cells, respectively (21) . Misexpression of Arx in ␤-cells or Pax4 in ␣-cells resulted in the transdifferentiation to the opposite cell type (22, 23) , whereas merely reducing Arx expression in ␣-cells caused them to transdifferentiate into ␤-cells (24) , demonstrating a previously underappreciated plasticity in islet cell type fate. Taken together with our demonstration that loss of Fstl3 leads to increased activin action in Fstl3-null mice (25) , these transdifferentiation studies suggest a model whereby ␤-cell expansion in Fstl3 null mice results from increased activin signaling within islets that influences islet cell fate to favor ␣-to ␤-cell transdifferentiation. One hypothesis derived from this model is that activin treatment of ␣-cells will destabilize or suppress the ␣-cell phenotype and promote a ␤-cell phenotype.
To test this hypothesis, we analyzed gene expression in ␣-and ␤-cells in response to treatment with activins A or B. We found that activin suppressed expression of important ␣-cell genes, including Arx, and promoted the expression of ␤-cell genes in the ␣TC1-6 ␣-cell line and enhanced the expression of ␤-cell genes, including Pax4, in the INS-1E ␤-cell line. Activin similarly suppressed ␣-cell gene expression in sorted mouse ␣-cells. In both cell lines and primary cells, activins A and B signaled through phosphorylated (p) Smad2, whereas pSmad3 was undetectable. These results indicate that activin signaling induced alterations in gene expression that would favor ␣-to ␤-cell transdifferentiation and thus support the hypothesis that ␣-to ␤-cell transdifferentiation is involved in the ␤-cell hyperplasia identified in the Fstl3-null mice.
Materials and Methods

Tissue culture
␣TC1 clone 6 cells (␣TC1-6; CRL-2934), a mouse line selected for lack of insulin production (26) , and HEP3B cells (HB-8064), a human liver line, were obtained from American Type Culture Collection. INS-1E cells (C0018009), a rat pancreatic ␤-cell line, were obtained from AddexBio. ␣TC1-6 cells were grown in low-glucose DMEM containing L-glutamine and 110 mg/L sodium pyruvate (Life Technologies) and were supplemented with 15 mM HEPES, 0.1 nM nonessential amino acids, 1.5 g/L sodium bicarbonate, 2 g/L D-glucose, 10% heat inactivated fetal bovine serum, and 1% penicillin-streptomycin. HEP3B cells, which were used as controls for Smad activity, were grown in high-glucose DMEM containing L-glutamine and 110 mg/L sodium pyruvate (Life Technologies) and were supplemented with 10% heat-inactivated fetal bovine serum and 1% penicillin-streptomycin. INS-1E cells were grown in RPMI 1640 medium (Sigma) containing L-glutamine and sodium bicarbonate supplemented with 10 mM HEPES, 50 M ␤-mercaptoethanol, 10% heat-inactivated fetal bovine serum, and 1% penicillinstreptomycin. All cell lines were incubated in 5% CO 2 -95% air at 37°C and passaged at 70% confluence via trypsinization with 0.05% trypsin and 0.53 mM EDTA.
Islet isolation
Animals were used in accordance with all regulations and guidelines, and research protocols were approved by the Baystate Medical Center's Institutional Animal Care and Use Committee. Islets were isolated from 10-to 12-week-old C57BL6 male mice as previously described (27) . After isolation, islets were cultured for 24 hours in RPMI 1640 (11 mM glucose; Mediatech) sup-plemented with 10% heat inactivated fetal bovine serum and 1% penicillin-streptomycin and then cultured with or without 3 nM activin A for 60 minutes, after which proteins were extracted as described below for cell lines. Additional islets were used for cell sorting as described below.
Cell sorting
Enriched populations of ␣-and ␤-cells were obtained using the method of Kohler et al (28) adapted for mouse islets. Briefly, isolated mouse islets were dispersed into single cells using trypsin-EDTA solution (450 mL, 37°C, 7-9 min), washed, and then placed in a low-glucose sorting buffer (Hanks' balanced salt solution plus 2.5 mM glucose; 1% BSA; 100 U/mL penicillin G; 100 g/mL streptomycin-sulfate; and 25 mM HEPES, pH 7.4) and filtered through a 0.2-m mesh screen. The dispersed cells were then sorted into primary ␣-cells and ␤-cells by fluorescence-activated cell sorter (BD FACSAria; BD Biosciences) using autofluorescence induced by low-glucose solution and gating strategies as previously described (28) . Cells were collected in ␣TC1-6 culture medium and placed into culture with ␣-cells cultured in ␣TC1-6 medium and ␤-cells cultured in islet medium. Some cells were fixed after 48 hours for immunocytochemistry, and others were cultured in the presence or absence of activin A or B (3 nM) for 24, 48, or 96 hours, after which the RNA was extracted and analyzed as described for the cell lines.
Gene expression
␣TC1-6 and/or INS-1E cells were plated on 24-well plates with 100 000 cells/well and treated 72 hours later with 3 nM activin A, 3 nM activin B, 3 nM BMP7, 3 nM TGF␤1, or 3 nM MSTN. RNA was extracted after 24, 48, and 96 hours (␣TC) or 24 hours (INS-1E) using the QIAGEN RNEasy microkit and reverse transcribed using SuperScript III reverse transcriptase (Invitrogen). Specific gene expression was determined by SYBR quantitative PCR (qPCR) using the QuantiTect SYBR Green PCR kit (QIAGEN), except for Pax4, which was assessed using Quantitect Taqman PCR kit and self-designed probe/primers. All PCRs were performed using an MX3005 qPCR machine (Agilent Technologies), and primers are listed in Supplemental Table 1 . A standard was created by reverse transcribing multiple aliquots of RNA pooled from islets and cell lines for mouse (␣TC cells and islet cells) or rat (INS-1E) cells and run at three dilutions in each PCR for each target. The result for each sample was interpolated from the standard curve and then normalized to the Rpl19 housekeeping gene, also interpolated off the standard curve. Because all PCR targets are expressed relative to the same standard, results for each target are comparable for a given species.
Immunocytochemistry
Sorted ␣-and ␤-cells were cultured for 48 hours, after which they were fixed in 4% glutaraldehyde, washed in PBS, treated with 0.2% Triton X-100 for 20 minutes, washed in PBS containing 0.5% donkey serum, blocked in PBS containing 5% donkey serum, incubated with antiinsulin (number A0564; Dako) and antiglucagon (number G2654; Sigma) primary antibodies (both at 1:150) overnight at 4ºC, washed with PBS containing 0.5% donkey serum, and incubated with Cy3 donkey antiguinea pig (number 706-165-148; Jackson ImmunoResearch) and goat antimouse Alexa Fluor 647 (number A21236; Life Technologies), both at 1:150, for 1 hour at room temperature. The cells were then washed in PBS and photographed.
Western blotting
Cells were plated on six-well plates until 90% confluent and then treated with 1 nM of activin A, activin B, TGF␤1, BMP4, or MSTN for 45-60 minutes (or 24 h activin A treatment for pancreatic duodenal homeobox-1 (PDX-1) and Aristaless related homeobox [ARX]). Cells were washed with cold PBS on ice and then lysed with radioimmunoprecipitation assay protein extraction buffer containing 0.1% sodium dodecyl sulfate, 0.5% sodium deoxycholate, and 1% Triton X-100 in PBS with protease (number 11836170001; Roche), and phosphatase (number P5726; Sigma) inhibitors.
Collected protein was centrifuged for 15 minutes at 12 000 rpm and the supernatant collected. Protein was quantified using the BCA protein assay kit (Thermo Scientific). Proteins (17-30 g of cell line and 20 -30 g of mouse islet) were electrophoresed using 10% miniprotean TGX gels and then transferred to a PVDF membrane using the Mini Trans-Blot Cell box (all SDS-PAGE and transfer materials are from Bio-Rad Laboratories). The blot was blocked in 3% milk (or 3% BSA in the case of pSmad1/5/9) in PBS with 0.05% Tween 20 (PBST) for 1 hour and then incubated with the primary antibody (pSmad2 and pSmad3 together, pSmad1/5/9, ARX, or PDX-1; see Table 1 for dilutions) in PBST/1% milk (2% BSA for pSmad1/5/9). After 24 hours rotating at 4º, the blot was put into a 1:5000 donkey antirabbit (number 711-035-152; Jackson ImmunoResearch) or antimouse (number 715-035-150; Jackson ImmunoResearch) antibody in 1% milk in PBST for 1 hour at room temperature. Blots were washed and the image was acquired using a G:BOX system (SyngeneD). After exposure of primary proteins, blots were stripped using a pH 2.2 buffer containing 0.2% sodium dodecyl sulfate, 1.5% glycine, 1% Tween 20, and 0.05% dithiothreitol in water reblocked in 3% milk, and put into a total Smad2/3, total Smad1, or ␤-actin (for ARX and PDX-1). Protein quantification was done using ImageJ (National Institutes of Health), and the blot images were subject to background subtraction prior to quantification.
Cell proliferation assay
Cells were plated on 96-well plates (20 000 -40 000 cells/ well) and treated with 4 nM activin A, 4 nM activin B, or 5.7 M insulin. The cells were analyzed daily using the CellTiter 96 AQueous nonradioactive cell proliferation assay (Promega) according to the manufacturer's recommendations.
Statistical analysis
Experiments with two groups were compared using t tests. When more than two treatment groups were analyzed, means were analyzed by ANOVA with a Bonferroni post hoc test for significance.
Results
Activin regulates gene expression in an ␣-cell line
We first used the ␣TC1-6 cell line that was subcloned from a mouse glucagonoma tumor cell line [␣TC1 (26)] based on the lack of insulin production and the ability to mimic rodent ␣-cells. Experiments were conducted for 24, 48, and 96 hours to determine whether activin could promote ␣-to ␤-cell transdifferentiation in vitro. At 24 hours of treatment, both activins A and B significantly suppressed expression of critical ␣-cell genes by 50% including Arx, MafB, and glucagon (Figure 1, A) . Activin treatment for 24 hours also suppressed ARX protein by 25%
( Figure 1 , D and E). Although expressed at several orders of magnitude less than ␣-cell genes, important ␤-cell genes such as Pax4, Pdx1, Ins1, and PC1/3 were not only detectable but were also significantly increased by treatment with activin A or B. By 48 hours of treatment, the effect on Arx and ␤-cell genes disappeared, whereas the reduction in glucagon and MafB was smaller but still significant (Figure 1, B) . At 96 hours of activin A or B treatment, Arx press.endocrine.org/journal/endoexpression was slightly but significantly enhanced, whereas that of glucagon and MafB remained significantly suppressed (Figure 1, C) . Interestingly, the expression of some ␤-cell genes were again enhanced, whereas others that were not altered previously were also enhanced, including PC2, Irs1, and Irs2. Taken together, activin's effects on the ␣TC1-6 ␣-cell line were consistent with activin enhancing a transition from an ␣-cell fate to that more resembling a ␤-cell expression profile.
Regulation of INS-1E gene expression by activin A and related ligands
We further explored the ability of activin to enhance expression of ␤-cell genes in the INS-1E rat ␤-cell line and compared this activity with related TGF␤ superfamily ligands that share some of activin's signaling pathways. We chose 24 hours because activin up-regulated ␤-cell gene expression in this time frame. Consistent with activin's effects in ␣TC1-6 cells, activin A induced a 10-fold increase in Pax4 expression, a transcription factor that can induce ␣-to ␤-cell transdifferentiation (22) as well as a smaller but significant increase in insulin expression (Figure 2, A) . Activin A treatment suppressed MafB, activin A subunit, Pdx1, and prohormone convertase (PC)-2 expression. MSTN recapitulated nearly all of activin's effects as expected from its use of the same Smad signaling pathway (Figure 2, A) . BMP7 and TGF␤1 appeared to have no effect on expression of analyzed genes with the exception that BMP7 slightly suppressed expression of PC1. Consistent with its effects on mRNA, we determined that activin also suppressed PDX-1 protein in these cells ( Figure  2, B) . These results indicate that the induction of Pax4 and insulin expression by activin that was observed in the ␣TC1-6 line is recapitulated by activin and MSTN in the INS-1E ␤-cell line, supporting the hypothesis that activin promotes the adoption of a ␤-cell identity.
Activin regulated gene expression in sorted mouse islet cells
To determine whether the effects of activin on gene expression observed in ␣-and ␤-cell lines is also valid for primary islet cells, we adapted the sorting method developed by Kohler et al (28) for human and rat islet cells to provide enriched populations of mouse ␣-and ␤-cells. This method takes advantage of natural fluorescence of ␤-cells as well as their larger size to separate populations of ␣-and ␤-cells, which can then be recovered for study. Dispersed islet cells from C57BL6 male mice were sorted and gates set as shown in Figure 3 , A. For this sort, ␣-cells comprised 18.8% of sorted cells, whereas the ␤-cell fraction was 54% (Figure 3, B) , indicating that most of the ␣-cells and a majority of the ␤-cells were recovered.
To characterize the degree of enrichment for the ␣-and ␤-cell populations obtained from cell sorting, we cultured cells for 48 hours to recover from sorting and then analyzed the cells by immunofluorescence. As expected, glucagon was primarily observed in the ␣-cell population, whereas insulin was observed in the ␤-cell population (Figure 3, C) . Contamination with the opposite cell type was less than 5%, and many of these cells were dual stained for both insulin and glucagon (Figure 3, C) . We further characterized these cells by qPCR after a 48-hour recovery period. Expression of ␣-cell genes in ␣-cells was increased over the ␤-cell pool by more than 20-fold for glucagon, MafB, Arx, and Irx2 (Figure 3, D) , whereas the expression of ␤-cell genes in ␤-cells was similarly enhanced compared with the ␣-cell population, including insulin, MafA, Pdx1, Glut2, and PC1 (Figure 3, D) . Taken together, these im- (n ϭ 4) . G, Pax4 was analyzed using Taqman PCR and was undetectable in ␣-cells (treated or not) or in untreated ␤-cells. However, after activin treatment, Pax4 was easily detectable, confirming results from cell lines (n ϭ 4). *, P Ͻ .05; **, P Ͻ .01; ***, P Ͻ .001. press.endocrine.org/journal/endo 2445 munofluorescent and qPCR results indicate that ␣-and ␤-cells were enriched to greater than 95% using this method and that these cells can be recovered for further analysis.
We then analyzed the effects of activin treatment on sorted islet cells with results expressed as fold difference from untreated to combine results from multiple experiments. Immediately after sorting and at 24 hours, we found that gene expression was significantly suppressed for all genes including the Rpl19 housekeeping gene (data not shown). By 48 hours mRNA expression levels returned and appeared to be leveling off, so we gave them 1 more day of exposure to ensure we could see differences with activin treatment. Activin treatment of ␣-cells suppressed glucagon mRNA expression by 66% as well as MafB and Arx by 30%, all similar to changes observed in the ␣TC1-6 cell line (Figure 3 , E). Activin had no effect on the expression of Irs1 and Irs2 or PC2. Although the expression of ␣-cell genes was detectable in the ␤-cell population ( Figure 3, F) , it was vastly reduced compared with the expression in the ␣-cell population (see Figure 3, D) . Nevertheless, MafB and Arx were significantly suppressed by activin treatment, suggesting that this expression might be from residual ␣-cells in this population. Activin had no significant effect on the expression of most ␤-cell genes, although PC2 and Irs2 tended to be elevated (Figure 3, F) .
However, treatment of ␤-cells with activin greatly enhanced Pax 4 expression from levels that were undetectable in untreated ␤-cells as well as treated or untreated ␣-cells (Figure 3, G) . Therefore, suppression of ␣-cell genes such as Arx and enhancement of Pax4 expression support the hypothesis that activin destabilizes the ␣-cell phenotype and promotes a ␤-cell fate.
Activin signals through Smad2 in cell lines and islet cells
Activin typically signals through the second messengers Smad2 and Smad3 that are phosphorylated by activin receptors after ligand binding (10) . We therefore examined whether activin signaled through this canonical pathway in islet cells and cell lines. Both activins A and B induced Smad2 phosphorylation in ␣TC1-6 cells, although pSmad3 was undetectable (Figure 4 , A) using an antibody that has been used successfully by others (29) . Similarly, both activins induced phosphorylation of Smad2 in INS-1E cells but again, pSmad3 was undetectable ( Figure  4 , C). Hep3B human hepatoma cells have previously been reported to contain both Smad2 and Smad3, so we analyzed Hep3B extracts as a control for both ␣TC1-6 cells and mouse islet extracts (Figure 4, E) . Although activin induced the phosphorylation of Smad2 in all three cell types, no pSmad3 was detectable (Figure 4, E) . However, total Smad3 was readily detectable in Hep3B cells.
It was recently reported that in liver cells, activin B can also signal via the Smad1/5/8 pathway that is usually reserved for BMP signaling (30) . Therefore, we examined the formation of pSmad1/5/8 in ␣TC1-6 and INS-1E cells in response to activin treatment. Neither activin A nor activin B induced phosphorylation of Smad1/5/8, although BMP4 induced a nearly 2-fold induction of both pSmad1 and pSmad5/8 ( Figure 4, B and D) . On the other hand, MSTN suppressed the basal phosphorylation in INS-1E cells (Figure 4, D) . These results indicate that in islets and islet cell lines, activins A and B phosphorylation of Smad2 and not Smad1/5/8.
Activin suppresses proliferation in ␣TC1-6 cells
Regulation of gene expression can be associated with altered cellular proliferation status. We therefore investigated whether activin A or B treatment altered proliferation of ␣TC1-6 cells, and we chose 4 nM to ensure that sufficient activin would be present at the end of the experiment. By 72 hours for activin B and 96 hours for activin A, proliferation was significantly inhibited, whereas insulin treatment had no significant effect on cell proliferation ( Figure 5 ). These results demonstrate that both activins A and B inhibit proliferation of ␣TC1-6 cells. Whether this effect is directly linked to activin's suppression of important ␣-cell gene expression remains to be determined.
Discussion
We previously demonstrated that the loss of the activin antagonist Fstl3 resulted in ␤-cell hyperplasia and enlarged islets in a setting of enhanced glucose tolerance and insulin sensitivity (19, 20) , although ␤-cell proliferation was unaltered (20) . This suggests that when released from negative regulation, activin can induce ␤-cell expansion. The recent demonstration that ␣-cells can be reprogrammed into ␤-cells (22, 24, 31) along with the observed reduction in ␣-cell compliment in Fstl3-null islets over time (20) suggested the hypothesis that within islets, increased activin signaling in the absence of the Fstl3 antagonist enhanced ␣-to ␤-cell transdifferentiation. To identify potential mechanisms for this process, we determined the role of activin in regulating the expression of important ␣-and ␤-cell genes, including those shown to be critical for fate determination (21) . Our results are consistent with a model in which increased activin signaling suppresses Arx expression and promotes Pax4 expression in ␣-cells. In the context of the Fstl3-null mouse, our results support the hypothesis that increased activin signaling destabilized the ␣-cell phenotype and promoted a ␤-cell fate.
In ␣TC1-6 cells, a widely used model for ␣-cell biology that does not produce insulin (26), we found that both activin A and B suppressed the expression of Arx, glucagon, and MafB by nearly 50% at 24 hours, an effect that continued for 96 hours for MafB and glucagon. Our results showing reduced glucagon and Arx expression upon activin A exposure confirm previous results (32) and extend this to MafB and activin B as well as to suppression of ARX protein. Because MafB regulates glucagon mRNA synthesis (33), our results suggest that activin may suppress glucagon gene expression, at least in part, through the inhibition of MafB synthesis. Although expressed at much lower absolute levels, we also found that critical ␤-cell genes were up-regulated in ␣TC1-6 cells by activins A and B treatment for 24 or 96 hours, including Pax4, Pdx1, insulin, and PC1/3. It is not clear why most effects on gene expression were not observed at 48 hours or why in certain instances, such as for insulin and PC1/3 at 24 hours, activin A stimulated expression, whereas activin B did not. We attempted to extend the culture of ␣TC1-6 cells for longer periods to examine whether ␣-to ␤-cell reprogramming could be induced, but the cells died after 7 days without becoming ␤-cells. It is possible that during selection of the ␣TC1-6 subclone based on its lack of insulin secretion (26) , a cell line that was incapable of fully transdifferentiating was isolated. Alternatively, these observations may indicate that activin plays more of a facilitating role to destabilize the differentiated ␣-cell phenotype, which is then induced to transdifferentiate by additional islet factors.
To determine whether activin treatment could induce expression of ␤-cell genes, we used the INS-1E rat ␤-cell line. Activin A stimulated the expression of the ␤-cell fate, press.endocrine.org/journal/endodetermining gene Pax4 more than 10-fold, as did MSTN, which is expressed in mouse islets (27) and uses the same second messengers as activin (10) . These results confirm and extend observations reported for rat islets (34) . In addition, activin and MSTN slightly but significantly enhanced insulin expression and suppressed Pdx1 expression in these cells. Interestingly, we found that INS-1E cells also synthesize MafB mRNA, a gene usually expressed in ␣-cells and is critical for ␣-cell function, and furthermore, activin suppressed MafB levels as observed in ␣TC1-6 cells. In fact, this suppression of MafB by activin was also observed in primary ␤-cells, suggesting that MafB can be produced in both ␣-and ␤-cells and is similarly regulated, at least in part, by activin. To expand these observations to primary islet cells, we adapted a cell-sorting protocol that relied on natural fluorescence of ␤-cells and produced enriched ␣-and ␤-cell pools to greater than 95% based on gene expression and immunofluorescence staining of glucagon and insulin. We confirmed that activin treatment significantly suppressed expression of glucagon, MafB, and Arx in sorted ␣-cells. However, activin treatment did not induce ␤-cell gene expression as observed in ␣TC1-6 cells. In sorted ␤-cells, activin again suppressed ␣-cell gene expression but had little detectable effect on ␤-cell gene expression, except for Pax4, which was undetectable in ␣-cells or untreated ␤-cells but was highly expressed after activin treatment in ␤-cells. Enhanced Pax4 expression by activin agrees with our observation in INS-1E cells as well as previous observations (34) . The effects on ␣-cell gene expression in the sorted ␤-cell pool likely reflects residual ␣-cells in this population because the absolute expression levels were much lower than in the ␣-cell population, although we cannot exclude reduced ␣-cell gene expression in ␤-cells. Nevertheless, the suppression of Arx, MafB, and glucagon in primary ␣-cells and enhanced Pax4 expression in ␤-cells is consistent with our observations in cell lines. Because Arx is required to specify ␣-cell formation in the pancreas (21) and suppression of Arx expression in ␣-cells is sufficient to induce reprogramming of these cells to ␤-cells (24), our results suggest that within adult mouse islet cells, activin may suppress or destabilize the ␣-cell phenotype and promote transition to a ␤-cell phenotype through the suppression of Arx biosynthesis.
Although we observed only a 25% decrease in ARX protein with 24 hours of activin treatment that may be insufficient to induce transdifferentiation, it is possible that the half-life of ARX is longer than its mRNA so that longer treatment times simulating the in vivo environment might achieve greater ARX reduction. Nevertheless, our results are consistent with our model that activin-induced ␣-to ␤-cell transdifferentiation is enhanced in Fstl3 null mice, leading to the observed ␤-cell hyperplasia and reduced ␣-cell compliment (19, 20) . Moreover, the decrease in Pdx1 and Glut2 expression in response to activin is interesting in that it was previously reported that ␤-cells within islets exist in several developmental states and that reduced Pdx1 and Glut2 were characteristic of the more immature ␤-cell population (6, 35, 36) . This might be expected for newly transdifferentiated ␤-cells and would thus be consistent with the proposed model that activin promotes ␣-to ␤-cell transdifferentiation in vivo.
Although the canonical signaling pathway for activin, TGF␤, growth differentiation factor 11, and MSTN uses both Smad2 and Smad3 second messengers (10), it is not clear that this is always the case or that the two Smads are equally used by all ligands. For example, TGF␤ was previously reported to induce Smad3 phosphorylation in rat islet cells and the TGF␤ effects could be inhibited by suppressing Smad3 expression (15), although Smad2 was not investigated. On the other hand, mouse islets were hypertrophic and less functional in Smad-2 null heterozygotes (37) and Smad2 disruption in mouse ␤-cells resulted in impaired insulin secretion but islet hyperplasia probably due to compensation for hyperglycemia (38) . Wu et al (13) recently reported that activin A more strongly phosphorylated pSmad2 relative to Smad3, whereas activin B preferred pSmad3 in INS-1E cells and mouse islets, with overexpression of Smad3 inhibiting insulin release, although whether these differences are functional in vivo remains controversial (14) . Although we probed blots for both pSmad2 and pSmad3, we detected only pSmad2 in ␣TC1-6 cells, INS-1E cells, and mouse islets. Total Smad3 was also undetectable in ␣TC1-6 cells, INS-1E cells, and mouse islets, although we could easily detect total Smad3 in control Hep3B hepatoma cells. Both Smad2 and Smad3 mRNA were detectable and nearly equal by qPCR in islet cells and cell lines (reference 27 and data not shown). It is therefore unclear why pSmad3 was undetectable under conditions in which pSmad2 was clearly observable, even in the control Hep3B cell line.
The pSmad3 antibody and blotting conditions we used had been previously used for immunoblotting pSmad3 in INS-1E cells in response to Nodal activation, although pSmad2 was not investigated in that study (29) . We tested simultaneous or sequential application of pSmad2 and pSmad3 antibodies but never detected a pSmad3 band in any cell line or primary cell. It remains possible that pSmad3 is present but below the detection threshold for this antibody at the protein load used, although large differences in pSmad2 and pSmad3 have not been previously noted. Nevertheless, our results demonstrate that both activins A and B induce their effects in ␣TC1-6 cells, INS1 cells, and mouse islets, at least via pSmad2, although we cannot exclude signaling through pSmad3 or noncanonical pathways such as the p38 MAPK pathway (39) or the ERK1/ERK2 MAPK pathway (40) .
Unlike activin and its related TGF␤ superfamily ligands, BMPs and their related ligands use one or more of pSmad1, pSmad5, or pSmad8/9 as second messengers. However, activin B was recently shown to signal via pSmad1/5/8 in human HepG2 liver cells (30), so we extended our investigation to determine whether activin B also uses Smad1/5/8 in islet cells. Neither activin A nor activin B induced the phosphorylation of these Smads in ␣TC1-6 or INS1 cells, although phosphorylation was clearly induced by BMP4. Therefore, it appears that the noncanonical pSmad1/5/8 pathway is not used by activin in islet cell lines. Interestingly, MSTN significantly inhibited basal pSmad1/5/8 phosphorylation, suggesting that in addition to the use of pSmad2/3 for signaling, MSTN simultaneously inhibits BMP-mediated activity. TGF␤ has been shown to inhibit BMP signaling in several bone cell lines via at least two different mechanisms including direct interaction of Smad3 and Smad1/5 and specifically not involving Smad2 (41, 42) . This suggests that studies of Smad3 involving its knockdown or deletion (13, 15) may involve, at least in part, up-regulation of BMP signaling, which has positive effects on ␤-cell function (16) . Nevertheless, our results support Smad2/3 as the primary signaling pathway for activins A and B. Additional studies in which Smad2 expression is eliminated will be required to determine whether activin's effects on gene expression are mediated exclusively via this pathway or include pSmad3.
If activin signaling does in fact induce ␣-to ␤-cell transdifferentiation in Fstl3-null mice, then it might be expected that activin would also increase ␣-cell proliferation to replace ␣-cells lost via transdifferentiation into ␤-cells. In contrast, we found that activin A and B both suppressed proliferation in ␣TC1-6 cells, although insulin had no effect. This confirms a previous study showing activin A inhibition of ␣-cell line proliferation (32) and extends the observation to activin B as well. However, insulin was previously reported to induce proliferation in ␣TC1 cells in a dose-dependent manner (43) , but the maximal dose in that study had no effect in ␣TC1-6 cells in our experiments. It is possible that the ␣TC1-6 subclone, although selected based on lack of insulin expression (26) , is also defective in insulin response because we were also unable to detect pAkt in these cells after 10 minutes of insulin treatment (data not shown). Taken together, these results suggest that in islets, activin and insulin may counterregulate ␣-cell proliferation. In addition, the reduced ␣-cell proliferation in response to activin would be consistent with the decreased ␣-cell content in Fstl3-null islets (20) .
Our results demonstrate that activin treatment suppressed the expression of Arx, glucagon, and MafB in ␣-cells, all of which are required to maintain the ␣-cell phenotype and function. Because the reduction of Arx alone was sufficient to induce ␣-to ␤-cell transdifferentiation (24), our results are consistent with the hypothesis that activin destabilizes the ␣-cell phenotype, which may then facilitate, directly or indirectly, induction of transdifferentiation into ␤-cells. Such a process could explain ␤-cell expansion observed in Fstl3-null mice (19) .
